Psilocybin and confronting mortality — experiences and the end-of-life research

The Hopkins/NYU cancer distress trials (Griffiths et al., Ross et al. 2016) showed something remarkable: a single psilocybin session produced lasting reductions in death anxiety and existential distress in people facing terminal illness. Mystical-type experience correlated with outcome — people who had profound experiences of unity or transcendence showed the most sustained improvement. The mechanism seems to be experiential, not pharmacological.

My experience: not terminally ill, but my father's death three years ago created acute mortality awareness that affected daily functioning. A high-dose psilocybin session (guided, supported) produced an experience of what I can only describe as contact with death as a dimension rather than an event. The fear didn't disappear but it changed quality — less like dread and more like orientation. I don't have a framework that fully explains this.

The philosophical literature on death anxiety — Yalom, Heidegger, Buddhist teachings — provides some conceptual scaffolding for integration. The psilocybin experience can produce insight that parallels what these traditions point at, but through direct experience rather than intellectual understanding. Integration involves building a language and practice around what the experience revealed.